Synapse - Works

Results (13087)

Expectant management of extranodal marginal zone lymphoma of bronchial-associated lymphoid tissue (BALT)

Meeting Abstract

Leyfman, Y.; Joffe, E.; Drill, E.; Rajeeve, S.; Zelenetz, A. D.; Palomba, M. L. L.; Moskowitz, C. H.; Portlock, C. S.; Noy, A.; Horwitz, S. M.; more...
Blood (2019)

Fulltext@MSK | Save

Efficacy and safety of carfilzomib-lenalidomide-dexamethasone (KRd) in newly diagnosed multiple myeloma: Pooled analysis of 4 single-arm studies

Meeting Abstract

Landgren, O.; Attal, M.; Kazandjian, D.; Roussel, M.; Jasielec, J. K.; Dytfeld, D.; Anderson, A.; Kervin, T.; Iskander, K.; Mezzi, K.; more...
Blood (2019)

Fulltext@MSK | Save

Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study

Meeting Abstract

Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
Blood (2019)

Fulltext@MSK | Save

A phase 1 first-in-human study of the anti-CD38 dimeric fusion protein TAK-169 for the treatment of patients (pts) with relapsed or refractory multiple myeloma (RRMM) who are proteasome inhibitor (PI)- and immunomodulatory drug (IMiD)-refractory, including pts relapsed/refractory (R/R) or naïve to daratumumab (dara)

Meeting Abstract

Kumar, S. K.; Cornell, R. F.; Landgren, O.; Ailawadhi, S.; Higgins, J. P.; Willert, E. K.; Waltzman, R.; Lin, J.; Zhang, Y.; Lublinsky, A. R.; more...
Blood (2019)

Fulltext@MSK | Save

A pilot study of brentuximab vedotin combined with AVD chemotherapy and radiotherapy in patients with newly diagnosed early stage, unfavorable risk Hodgkin lymphoma

Meeting Abstract

Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L. E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S.; Drill, E.; more...
Blood (2019)

Fulltext@MSK | Save

Transcriptome profiling of pediatric myeloproliferative neoplasms demonstrates dysregulation of platelet-relevant genes and enrichment of inflammatory and JAK2 mediated complement pathways

Meeting Abstract

Kucine, N.; Leonti, A. R.; Krishnan, A.; Ries, R. E.; Levine, R. L.; Meshinchi, S.
Blood (2019)

Fulltext@MSK | Save

Acute leukemia with lineage infidelity: Mixed phenotype AML exhibits a distinct immunophenotype with clinical features overlapping mixed phenotype acute leukemia

Meeting Abstract

Kresch, M. P.; Xiao, W.; Menghrajani, K.; Famulare, C.; Patel, M. A.; Baik, J.; Roshal, M.; Levine, R. L.; Tallman, M. S.; Glass, J. L.
Blood (2019)

Fulltext@MSK | Save

Evaluation of biomarkers as predictors of blinatumomab toxicity and real-world management of blinatumomab toxicity in B-acute lymphoblastic leukemia patients

Meeting Abstract

King, A. C.; Park, J. H.; Geyer, M. B.
Blood (2019)

Fulltext@MSK | Save

Real world chart review of blinatumomab to treat patients with high disease burden of relapsed or refractory B-cell precursor acute lymphoblastic leukemia

Meeting Abstract

King, A. C.; Bolanos, R.; Velasco, K.; Tu, H.; Zaman, F.; Geyer, M. B.; Park, J. H.
Blood (2019)

Fulltext@MSK | Save

Evaluation of tagraxofusp (SL-401) alone and in combination with ruxolitinib for the treatment of myeloproliferative neoplasms

Meeting Abstract

Krishnan, A.; Pagane, M.; Roshal, M.; McGovern, E.; Stone-Molloy, Z.; Chen, J.; Brooks, C.; Levine, R. L.; Rampal, R. K.
Blood (2019)

Fulltext@MSK | Save